Company to Use Proceeds to Advance Programs for Duchenne Muscular Dystrophy.
Solid Biosciences is proud to join the global Rare Disease community to recognize Rare Disease Day 2017.
As we move into 2017, I want to reflect on our journey since founding Solid three years ago and to outline what we hope to accomplish in the coming year.
The Duchenne Research Fund (DRF) provided Solid with a research grant of $600,000 to support its LTBP4 program to combat fibrosis and to support novel biomarker work in Duchenne muscular dystrophy (DMD).
Grant from Duchenne UK to fund research to better understand the potential benefits of statins in patients with Duchenne muscular dystrophy (DMD).
Company Expands Presence with London Office to Support Clinical Development.
Grants from Alex’s Wish and Duchenne Now will support important work to further Solid’s efforts to solve Duchenne muscular dystrophy.
Biologic candidate has the potential to complement gene therapy by improving muscle function.
It has been an exciting and emotional time for our Duchenne muscular dystrophy (DMD) community.
Please subscribe to receive our latest news